Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4283869 | 0.91 | POLB (0.44) | HRH4HRH3POLBKMT2A | |
| SCHEMBL4284757 | 0.85 | GPR88 (0.35) | HRH4HRH3POLBL3MBTL1 | |
| SCHEMBL4294620 | 0.82 | CYP19A1 (0.36) | HRH4HRH3DPP4 | |
| SCHEMBL4295181 | 0.82 | DPP4 (0.33) | DPP4 | |
| SCHEMBL4292395 | 0.78 | ALDH1A1 (0.47) | POLBKMT2A | |
| SCHEMBL4290450 | 0.78 | POLB (0.40) | HRH4HRH3DPP4NOTUMPOLB | |
| Hydrochloric Acid SCHEMBL4291831 | 0.77 | POLB (0.41) | HRH4HRH3DPP4NOTUMPOLB | |
| SCHEMBL4285493 | 0.75 | LMNA (0.36) | KMT2AL3MBTL1 | |
| SCHEMBL4284114 | 0.74 | MCHR1 (0.35) | — | |
| SCHEMBL4788402 | 0.71 | CA1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | HRH4 616/4885HRH3 1248/4885DPP4 113/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | HRH4 616/4885HRH3 1248/4885DPP4 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.